Preclinical Efficacy of Anecortave Acetate

Abbot F. Clark

doi:10.1016/j.survophthal.2006.11.004

Preclinical Efficacy of Anecortave Acetate

Abbot F. Clark

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Anecortave acetate is a unique ocular angiostatic cortisene that has broad-based anti-angiogenic activity in 14 different preclinical models of neovascularization, across multiple species and inducers of neovascularization. Anecortave acetate is being tested clinically for inhibition of choroidal neovascularization associated with age-related macular degeneration.

Original language	English
Pages (from-to)	S41-S48
Journal	Survey of Ophthalmology
Volume	52
Issue number	1 SUPPL.
DOIs	https://doi.org/10.1016/j.survophthal.2006.11.004
State	Published - 1 Jan 2007

Keywords

age-related macular degeneration
anecortave acetate
choroidal neovascularization
efficacy
preclinical

Access to Document

10.1016/j.survophthal.2006.11.004

Cite this

@article{9a1e9dd9a59f441485e54470c6aeec03,

title = "Preclinical Efficacy of Anecortave Acetate",

abstract = "Anecortave acetate is a unique ocular angiostatic cortisene that has broad-based anti-angiogenic activity in 14 different preclinical models of neovascularization, across multiple species and inducers of neovascularization. Anecortave acetate is being tested clinically for inhibition of choroidal neovascularization associated with age-related macular degeneration.",

keywords = "age-related macular degeneration, anecortave acetate, choroidal neovascularization, efficacy, preclinical",

author = "Clark, {Abbot F.}",

year = "2007",

month = jan,

day = "1",

doi = "10.1016/j.survophthal.2006.11.004",

language = "English",

volume = "52",

pages = "S41--S48",

journal = "Survey of Ophthalmology",

issn = "0039-6257",

publisher = "Elsevier USA",

number = "1 SUPPL.",

}

TY - JOUR

T1 - Preclinical Efficacy of Anecortave Acetate

AU - Clark, Abbot F.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Anecortave acetate is a unique ocular angiostatic cortisene that has broad-based anti-angiogenic activity in 14 different preclinical models of neovascularization, across multiple species and inducers of neovascularization. Anecortave acetate is being tested clinically for inhibition of choroidal neovascularization associated with age-related macular degeneration.

AB - Anecortave acetate is a unique ocular angiostatic cortisene that has broad-based anti-angiogenic activity in 14 different preclinical models of neovascularization, across multiple species and inducers of neovascularization. Anecortave acetate is being tested clinically for inhibition of choroidal neovascularization associated with age-related macular degeneration.

KW - age-related macular degeneration

KW - anecortave acetate

KW - choroidal neovascularization

KW - efficacy

KW - preclinical

UR - http://www.scopus.com/inward/record.url?scp=33846250377&partnerID=8YFLogxK

U2 - 10.1016/j.survophthal.2006.11.004

DO - 10.1016/j.survophthal.2006.11.004

M3 - Article

C2 - 17240256

AN - SCOPUS:33846250377

SN - 0039-6257

VL - 52

SP - S41-S48

JO - Survey of Ophthalmology

JF - Survey of Ophthalmology

IS - 1 SUPPL.

ER -

Preclinical Efficacy of Anecortave Acetate

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this